Top

Published in:

01-12-2017 | Original Investigation

Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals

Authors: Saverio G. Parisi, Samantha Andreis, Monica Basso, Silvia Cavinato, Renzo Scaggiante, Marzia Franzetti, Massimo Andreoni, Giorgio Palù, Anna Maria Cattelan

Published in: Medical Microbiology and Immunology | Issue 6/2017

Abstract

This longitudinal study described cellular HIV-DNA changes and their correlation with HIV low-level plasma viremia (LLV) in HIV–HCV co-infected patients on successful antiretroviral and anti-HCV therapy by treatment with direct-acting antivirals (DAA). Thirty-nine patients were examined prior to the start of DAA (T0), after week 12 (T1) and 24 weeks (T2) of anti-HCV therapy. Cellular PBMC HIV-DNA was analysed as an absolute value and as the percentage of increase or decrease from T0 to T2. Patients were classified as having undetectable plasma HIV viraemia (UV) or LLV in the year before the start of anti-HCV treatment and within the T0–T2 study period. Thirty-five patients (89.7%) of the 39 subjects enrolled had the same plasma HIV viraemia control in the year before HCV treatment and in the T0–T2 interval. The HIV-DNA value at T0 and at T2 was higher in patients with LLV than in subjects with UV (p = 0.015 and p = 0.014, respectively). A similar proportion of patients with LLV and UV experienced an increase or decrease of HIV-DNA from T0 to T2. The percentage increase in HIV-DNA value (262.8%) from T0 to T2 was higher compared to the decrease (43.5%) in patients with UV (p = 0.012), and it was higher compared to the percentage increase in HIV-DNA value reported in subjects with LLV (262.8 versus 49%, p = 0.026). HIV–HCV co-infected patients experienced a multifaceted perturbation of cellular HIV-DNA levels within a 24-week period during anti-HCV treatment; the extent of the phenomenon was greater in subjects with UV. Fast HCV-RNA clearance seemed to have a greater influence on the cellular reservoir than on plasma HIV-RNA.

Available only for authorised users

Mandorfer M, Schwabl P, Steiner S, Reiberger T, Peck-Radosavljevic M (2016) Advances in the management of HIV/HCV coinfection. Hepatol Int 10:424–435. doi:10.1007/s12072-015-9691-4 CrossRefPubMed

Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA (2016) Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA 316:191–210. doi:10.1001/jama.2016.8900 CrossRefPubMedPubMedCentral

European AIDS Clinical Society Guidelines, Version 8.0—June 2016. http://www.eacsociety.org. Accessed 18 July 2016

Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, Chen P, Chen BK, Klotman ME, Bansal MB (2010) Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 52:612–622. doi:10.1002/hep.23679 CrossRefPubMedPubMedCentral

Shmagel KV, Saidakova EV, Shmagel NG, Korolevskaya LB, Chereshnev VA, Robinson J, Grivel JC, Douek DC, Margolis L, Anthony DD, Lederman MM (2016) Systemic inflammation and liver damage in HIV/hepatitis C virus coinfection. HIV Med 17:581–589. doi:10.1111/hiv.12357 CrossRefPubMedPubMedCentral

Sumpter R Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM, Gale M Jr (2005) Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 79:2689–2699. doi:10.1128/JVI.79.5.2689-2699.2005 CrossRefPubMedPubMedCentral

Mavigner M, Delobel P, Cazabat M, Dubois M, L’faqihi-Olive FE, Raymond S, Pasquier C, Marchou B, Massip P, Izopet J (2009) HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 4:e7658. doi:10.1371/journal.pone.0007658 CrossRefPubMedPubMedCentral

Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H (2008) Residual viraemia in HIV-1-infected patients with plasma viral load <20 copies/mL is associated with increased blood levels of soluble immune activation markers. Scand J Immunol 68:652–660CrossRefPubMed

Baroncelli S, Pirillo MF, Galluzzo CM, Antoni AD, Ladisa N, Francisci D, d’Ettorre G, Segala D, Vivarelli A, Sozio F, Cirioni O, Weimer LE, Fragola V, Parruti G, Floridia M (2015) Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens. AIDS Res Hum Retrovir 31:71–77. doi:10.1089/AID.2014.0060 CrossRefPubMedPubMedCentral

10.

Pugliese P, Delpierre C, Cuzin L, Poizot-Martin I, Rey D, Saune K, Cottalorda J, Bettinger D, Delaugerre C, Hoen B, Dat AIDS Study Group (2013) An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy. HIV Med 14:509–515. doi:10.1111/hiv.12041 CrossRefPubMed

11.

Calcagno A, Motta I, Ghisetti V, Lo Re S, Allice T, Marinaro L, Milia MG, Tettoni MC, Trentini L, Orofino G, Salassa B, Di Perri G, Bonora S (2015) HIV-1 very low level viremia is associated with virological failure in highly active antiretroviral treatment-treated patients. AIDS Res Hum Retrovir 31:999–1008. doi:10.1089/AID.2015.0102 CrossRefPubMed

12.

Cho H, Kikuchi M, Li Y, Nakamoto N, Amorosa VK, Valiga ME, Chang KM (2014) Induction of multiple immune regulatory pathways with differential impact in HCV/HIV coinfection. Front Immunol 5:265. doi:10.3389/fimmu.2014.00265 CrossRefPubMedPubMedCentral

13.

Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS (1998) Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 95:8869–8873CrossRefPubMedPubMedCentral

14.

Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF (2007) Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 5:95–106. doi:10.1038/nrmicro1580 CrossRefPubMed

15.

Fischer M, Joos B, Niederöst B, Kaiser P, Hafner R, von Wyl V, Ackermann M, Weber R, Günthard HF (2008) Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology 5:107. doi:10.1186/1742-4690-5-107 CrossRefPubMedPubMedCentral

16.

Parisi SG, Andreis S, Mengoli C, Scaggiante R, Ferretto R, Manfrin V, Cruciani M, Giobbia M, Boldrin C, Basso M, Andreoni M, Palù G, Sarmati L (2012) Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy. J Clin Microbiol 50:258–263. doi:10.1128/JCM.06022-11 CrossRefPubMedPubMedCentral

17.

Parisi SG, Sarmati L, Andreis S, Scaggiante R, Cruciani M, Ferretto R, Manfrin V, Basso M, Andreoni M, Mengoli C, Palù G (2015) Strong and persistent correlation between baseline and follow-up HIV-DNA levels and residual viremia in a population of naïve patients with more than 4 years of effective antiretroviral therapy. Clin Microbiol Infect 21:288.e5–288.e7. doi:10.1016/j.cmi.2014.10.009 CrossRef

18.

Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M, Vandekerckhove L (2016) Integrated and total HIV-1 DNA predict ex vivo viral outgrowth. PLoS Pathog 12:e1005472. doi:10.1371/journal.ppat.1005472 CrossRefPubMedPubMedCentral

19.

Wong JK, Günthard HF, Havlir DV, Zhang ZQ, Haase AT, Ignacio CC, Kwok S, Emini E, Richman DD (1997) Reduction of HIV-1-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci 94:12574–12579CrossRefPubMedPubMedCentral

20.

Sarmati L, Parisi SG, Nicastri E, d’Ettorre G, Andreoni C, Dori L, Gatti F, Montano M, Buonomini AR, Boldrin C, Palù G, Vullo V, Andreoni M (2007) Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens. J Med Virol 79:880–886. doi:10.1002/jmv.20914 CrossRefPubMed

21.

Sarmati L, Parisi SG, Nicastri E, d’Ettorre G, Palmisano L, Andreotti M, Andreoni C, Giuliano M, Gatti F, Boldrin C, Palù G, Vullo V, Vella S, Andreoni M (2005) Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy. J Clin Microbiol 43:6183–6185. doi:10.1128/JCM.43.12.6183-6185.2005 CrossRefPubMedPubMedCentral

22.

Widera M, Dirks M, Bleekmann B, Jablonka R, Däumer M, Walter H, Ehret R, Verheyen J, Esser S (2017) HIV-1 persistent viremia is frequently followed by episodes of low-level viremia. Med Microbiol Immunol 206:203–215CrossRefPubMedPubMedCentral

23.

Morón-López S, Gómez-Mora E, Salgado M, Ouchi D, Puertas MC, Urrea V, Navarro J, Jou A, Pérez M, Tural C, Clotet B, Montaner LJ, Blanco J, Crespo M, Martinez-Picado J (2016) Short-term treatment with interferon alfa diminishes expression of HIV-1 and reduces CD4 + T-cell activation in patients coinfected with HIV and hepatitis C Virus and receiving antiretroviral therapy. J Infect Dis 213:1008–1012. doi:10.1093/infdis/jiv521 CrossRefPubMed

24.

Jiao YM, Weng WJ, Gao QS, Zhu WJ, Cai WP, Li LH, Li HJ, Gao YQ, Wu H (2015) Hepatitis C therapy with interferon-α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients. Antivir Res 118:118–122. doi:10.1016/j.antiviral.2015.03.011 CrossRefPubMed

25.

Sun H, Buzon MJ, Shaw A, Berg RK, Yu XG, Ferrando-Martinez S, Leal M, Ruiz-Mateos E, Lichterfeld M (2014) Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients. J Infect Dis 209:1315–1320. doi:10.1093/infdis/jit628 CrossRefPubMed

26.

Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, Carrieri P, Chas J, Poizot-Martin I, Gervais A, Dominguez S, Neau D, Zucman D, Billaud E, Morlat P, Aumaitre H, Lascoux-Combe C, Simon A, Bouchaud O, Teicher E, Bani-Sadr F, Alric L, Vittecoq D, Boué F, Duvivier C, Valantin MA, Esterle L, Dabis F, Sogni P, Salmon D, ANRS CO13 HEPAVIH study group (2017) Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients—French ANRS CO13 HEPAVIH cohort. J Hepatol 67:23–31. doi:10.1016/j.jhep.2017.02.012 CrossRefPubMed

27.

Sarmati L, D’Ettorre G, Parisi SG, Andreoni M (2015) HIV replication at low copy number and its correlation with the HIV reservoir: a clinical perspective. Curr HIV Res 13:250–257. doi:10.2174/1570162X13666150407142539 CrossRefPubMedPubMedCentral

28.

Sánchez-Conde M, Montes-Ramírez ML, Miralles P, Alvarez JM, Bellón JM, Ramírez M, Arribas JR, Gutiérrez I, López JC, Cosín J, Alvarez E, González J, Berenguer J (2010) Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 17:280–286. doi:10.1111/j.1365-2893.2009.01180 CrossRefPubMed

29.

Hepatitis Drug Interactions website, website, http://www.hep-druginteractions.org. Accessed 19 July 2016

30.

Gianella S, Anderson CM, Vargas MV, Richman DD, Little SJ, Morris SR, Smith DM (2013) Cytomegalovirus DNA in semen and blood is associated with higher levels of proviral HIV DNA. J Infect Dis 207:898–902. doi:10.1093/infdis/jis777 CrossRefPubMed

31.

Gianella S, Anderson CM, Var SR, Oliveira MF, Lada SM, Vargas MV, Massanella M, Little SJ, Richman DD, Strain MC, Pérez-Santiago J, Smith DM (2016) Replication of human herpes viruses is associated with higher HIV DNA levels during antiretroviral therapy started at early phases of HIV infection. J Virol 90:3944–3952. doi:10.1128/JVI.02638-15 CrossRefPubMedPubMedCentral

32.

Debes JD, de Knegt RJ, Boonstra A (2017) The path to cancer and back: immune modulation during hepatitis C virus infection, progression to fibrosis and cancer, and unexpected roles of new antivirals. Transplantation 101:910–915. doi:10.1097/TP.0000000000001623 CrossRefPubMed

33.

Langhans B, Nischalke HD, Krämer B, Hausen A, Dold L, van Heteren P, Hüneburg R, Nattermann J, Strassburg CP, Spengler U (2017) Increased peripheral CD4 + regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C. J Hepatol 66:888–896. doi:10.1016/j.jhep.2016.12.019 CrossRefPubMed

34.

Hengst J, Falk CS, Schlaphoff V, Deterding K, Manns MP, Cornberg M (2016) Wedemeyer H (2016) Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis 214:1965–1974CrossRefPubMed

35.

Hengst J, Strunz B, Deterding K, Ljunggren HG, Leeansyah E, Manns MP, Cornberg M, Sandberg JK, Wedemeyer H, Björkström NK (2016) Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur J Immunol 46:2204–2210. doi:10.1002/eji.201646447 CrossRefPubMed

36.

Chen F, Zhang J, Wen B, Luo S, Lin Y, Ou W, Guo F, Tang P, Liu W, Qu X (2016) HBV/HCV dual infection impacts viral load, antibody response, and cytokine expression differently from HBV or HCV single infection. Sci Rep 6:39409. doi:10.1038/srep39409 CrossRefPubMedPubMedCentral

37.

Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, Squadrito G, Tono N, Associazione Italiana Studio Fegato Cooperative Group (2006) Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 43:100–107. doi:10.1002/hep.20944 CrossRefPubMed

38.

Reuter S, Oette M, Wilhelm FC, Beggel B, Kaiser R, Balduin M, Schweitzer F, Verheyen J, Adams O, Lengauer T, Fätkenheuer G, Pfister H, Häussinger D (2011) Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients. Med Microbiol Immunol 200:39–49. doi:10.1007/s00430-010-0172-z CrossRefPubMed

39.

Boritz EA, Darko S, Swaszek L, Wolf G, Wells D, Wu X, Henry AR, Laboune F, Hu J, Ambrozak D, Hughes MS, Hoh R, Casazza JP, Vostal A, Bunis D, Nganou-Makamdop K, Lee JS, Migueles SA, Koup RA, Connors M, Moir S, Schacker T, Maldarelli F, Hughes SH, Deeks SG, Douek DC (2016) Multiple origins of virus persistence during natural control of HIV infection. Cell 166:1004–1015. doi:10.1016/j.cell.2016.06.039 CrossRefPubMedPubMedCentral

40.

Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Kosakovsky Pond SL, Chung YS, Penugonda S, Chipman JG, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, Wolinsky SM (2016) Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530:51–56. doi:10.1038/nature16933 CrossRefPubMedPubMedCentral

41.

Kondo Y, Ueno Y, Kakazu E, Kobayashi K, Shiina M, Tamai K, Machida K, Inoue J, Wakui Y, Fukushima K, Obara N, Kimura O, Shimosegawa T (2011) Lymphotropic HCV strain can infect human primary naïve CD4 + cells and affect their proliferation and IFN-γ secretion activity. J Gastroenterol 46:232–241. doi:10.1007/s00535-010-0297-2 CrossRefPubMed

42.

Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, Kottilil S (2014) Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Investig 124:3352–3363. doi:10.1172/JCI75938 CrossRefPubMedPubMedCentral

43.

Stephan C, Baldauf HM, Barry J, Giordano FA, Bartholomae CC, Haberl A, Bickel M, Schmidt M, Laufs S, Kaderali L, Keppler OT (2014) Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients. J Antimicrob Chemother 69:2809–2818. doi:10.1093/jac/dku213 CrossRefPubMed

44.

Koelsch KK, Boesecke C, McBride K, Gelgor L, Fahey P, Natarajan V, Baker D, Bloch M, Murray JM, Zaunders J, Emery S, Cooper DA, Kelleher AD, PINT study team (2011) Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS 25:2069–2078. doi:10.1097/QAD.0b013e32834b9658 CrossRefPubMed

45.

Rossetti B, Meini G, Bianco C, Lamonica S, Mondi A, Belmonti S, Fanti I, Ciccarelli N, Di Giambenedetto S, Zazzi M, De Luca A (2017) Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA. J Clin Virol 91:18–24. doi:10.1016/j.jcv.2017.03.018 CrossRefPubMed

46.

Abad-Fernández M, Dronda F, Moreno A, Casado JL, Pérez-Elías MJ, Quereda C, Moreno S, Vallejo A (2015) Brief Report: Reduced cell-associated HTLV-2 DNA in antiretroviral treated HIV-1-HCV-coinfected patients who either received interferon-α/ribavirin-based hepatitis C therapy or had spontaneous HCV RNA clearance. J Acquir Immune Defic Syndr 69:286–290. doi:10.1097/QAI.0000000000000608 CrossRefPubMed

47.

Turci M, Pilotti E, Ronzi P, Magnani G, Boschini A, Parisi SG, Zipeto D, Lisa A, Casoli C, Bertazzoni U (2006) Coinfection with HIV-1 and human T-Cell lymphotropic virus type II in intravenous drug users is associated with delayed progression to AIDS. J Acquir Immune Defic Syndr 41:100–106. doi:10.1097/01.qai.0000179426.04166.12 CrossRefPubMed

48.

Massimo A, Teti E, Antinori A, Milazzoi L, Sollima S, Rizzardini G, Di Biagio A, Saracino A, Bruno R, Borghi V, De Luca A, Cattelan A, Hasson H, Taliani G, Monforte AD, Mastroianni CM, Di Perri G, Bigoni S, Puoti M, Spinetti A, Gori A, Boffa N, Bruno C, Giacometti A, Parruti G, Vullo V, Chirianni A, Pennica A, Pasquazzi C, Segala D, Sarmati L, SIMIT (Società Italiana di Malattie Infettive e Tropicali) (2017) Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV Co-Infection: results of an Italian compassionate use program. Clin Infect Dis 64:680–683. doi:10.1093/cid/ciw846 PubMed

49.

Bruno G, Saracino A, Fabrizio C, Scudeller L, Milano E, Dell’Acqua R, Ladisa N, Fasano M, Minniti S, Buccoliero G, Tartaglia A, Giammario A, Milella M, Angarano G (2017) Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study. Int J Antimicrob Agents 49:296–301. doi:10.1016/j.ijantimicag.2016.11.030 CrossRefPubMed

50.

Lacombe K, Fontaine H, Dhiver C, Metivier S, Rosenthal E, Antonini T, Valantin MA, Miailhes P, Harent S, Batisse D, Pageaux GP, Chas J, Aumaitre H, Dominguez S, Allegre T, Lafeuillade A, Billaud E, De Truchis P, Perre P, Leroy V, De Ledinghen V, Sogni P, Dabis F, Zhao Y, Filipovics A, Fedchuk L, Akremi R, Bennai Y, Salmon Ceron D (2017) Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a French early access cohort. J Acquir Immune Defic Syndr 75:97–107. doi:10.1097/QAI.0000000000001342 CrossRefPubMedPubMedCentral

51.

Russelli G, Pizzillo P, Iannolo G, Barbera F, Tuzzolino F, Liotta R, Traina M, Vizzini G, Gridelli B, Badami E, Conaldi PG (2017) HCV replication in gastrointestinal mucosa: potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation. PLoS One 12:e0181683. doi:10.1371/journal.pone.0181683 CrossRefPubMedPubMedCentral

52.

Tully DC, Hjerrild S, Leutscher PD, Renvillard SG, Ogilvie CB, Bean DJ, Videbech P, Allen TM, McKeating JA, Fletcher NF (2016) Deep sequencing of hepatitis C virus reveals genetic compartmentalization in cerebrospinal fluid from cognitively impaired patients. Liver Int 36:1418–1424. doi:10.1111/liv.13134 CrossRefPubMedPubMedCentral

53.

Svicher V, Ceccherini-Silberstein F, Antinori A, Aquaro S, Perno CF (2014) Understanding HIV compartments and reservoirs. Curr HIV/AIDS Rep 11:186–194. doi:10.1007/s11904-014-0207-y CrossRefPubMed

54.

Lambert-Niclot S, Flandre P, Valantin MA, Peytavin G, Duvivier C, Haim-Boukobza S, Algarte-Genin M, Yazdanpanah Y, Girard PM, Katlama C, Calvez V, Marcelin AG (2011) Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis 204:1211–1216. doi:10.1093/infdis/jir518 CrossRefPubMed

55.

Donath M, Wolf T, Stürmer M, Herrmann E, Bickel M, Khaykin P, Göpel S, Gute P, Haberl A, de Leuw P, Schüttfort G, Berger A, Stephan C, for Frankfurt HIV Cohort Study (2016) HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy. Med Microbiol Immunol 205:575–583CrossRefPubMed

Title: Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals
Authors: Saverio G. Parisi
Samantha Andreis
Monica Basso
Silvia Cavinato
Renzo Scaggiante
Marzia Franzetti
Massimo Andreoni
Giorgio Palù
Anna Maria Cattelan
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: Medical Microbiology and Immunology / Issue 6/2017
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-017-0518-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2017

Immune response against rickettsiae: lessons from murine infection models

Simultaneous analysis of multiple T helper subsets in leprosy reveals distinct patterns of Th1, Th2, Th17 and Tregs markers expression in clinical forms and reactional events

Burkholderia cepacia complex in cystic fibrosis in a Brazilian reference center

The impact of KIR–HLA genotype on hepatitis B virus clearance in Iranian infected individuals

Human parainfluenza virus type 2 polymerase complex recognizes leader promoters of other species belonging to the genus Rubulavirus

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials